Hybridon, Inc

From Wikipedia, the free encyclopedia

Hybridon, Inc (Amex: HBY) was a biotechnology company based in Cambridge, MA, specializing in the discovery and development of novel therapeutics and diagnostics using synthetic DNA, that merged with Idera Pharmaceuticals in 2004.

[edit] Notable investors

Hybridon was as notable for is interesting roster of investors as well as for its technologies and products. According to an SEC filing of May 4, 1999[1] Hybridon had a number of interesting investors with 5% or more ownership including:

  • Abdullah bin Mahfouz, son of the more widely-known Khalid bin Mahfouz (13/87%), along with the Bermuda-based Mahfouz proprietary Intercity Holdings (13.87%);
  • Yahia M. A. Laden (8.67%), half-brother of the more famous Osama bin Laden;
  • Nicris Limited, directed by Yehia bin Laden, and represented by Magnin Dunand et Associées (8.59%)
  • Faisal Finance Switzerland, the first Islamic bank registered in Switzerland, and a fully-owned subsidiary of Dar al-Maal al-Islami Trust, recently under investigation by the U.S. Department of Justice in two separate terrorism financing probes.[2] (6.58%).

[edit] External links

[edit] References

  1. ^ DEFR14A for Hybridon, Inc, filed 5/4/99
  2. ^ GLENN R. SIMPSON (January 31, 2007). Terror Inquiry Turns to Tax Law: Efforts to Probe Financing Of Islamic Extremists Centers on IRS Violations. Wall Street Journal.